Summary
The product Modalert 200 mg, manufactured by Sun Pharma, was analyzed to verify its active ingredient and potency. The sample was submitted and funded by Modawhale and tested by Janoshik Analytical, a laboratory specializing in pharmaceutical analysis. The analysis confirmed the presence of modafinil at a measured concentration of 205.34 mg per tablet, reflecting a 2.67% variance above the labeled specification of 200 mg.
Testing was initiated on 31 October 2024, the sample was received on 5 November 2024, and the analysis was completed on 11 November 2024. The slight variance observed is well within acceptable limits, indicating a consistent manufacturing standard. However, since the sample was submitted by the reseller, independent testing of market-purchased samples is recommended to ensure consistency across batches.
Detailed Report
Product Overview
- Manufacturer: Sun Pharma
- Product Name: Modalert 200 mg
- Active Ingredient: Modafinil
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral tablet
Sample Acquisition and Testing
- Task Number: #52187
- Testing Ordered: 31 October 2024
- Sample Received: 5 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Modawhale (Reseller)
- Analysis Paid For By: Modawhale
Testing Results
- Specification: 200 mg (as stated on the label)
- Measured Concentration: 205.34 mg
- Accuracy: 102.67% (2.67% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/52187_KT5NAC3Y1SPS
- Originally Published: https://thinksteroids.com/community/posts/3373596/
Evaluation of Reseller-Submitted Testing
The report demonstrates a high level of accuracy, with the measured concentration exceeding the labeled claim by 2.67%. While this highlights consistent quality control by Sun Pharma, it is important to note that the sample was submitted and funded by the reseller, Modawhale. Reseller-submitted samples may not represent typical market products, as they may selectively submit optimal batches for analysis. Cross-referencing with independent, third-party testing of market-acquired samples would provide additional confidence in product consistency.
Conclusion
The analysis confirms that Modalert 200 mg is manufactured with accurate dosing, with a minor variance of 2.67% above the label claim. This result reflects consistent manufacturing practices by Sun Pharma. However, consumers are advised to exercise caution and consider independent validation of market-purchased samples to mitigate potential biases associated with reseller-funded submissions.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases due to selective sample submissions. The findings pertain solely to the tested batch and may not represent all products under the same name. Readers are encouraged to cross-reference these results with independent third-party testing for additional validation and use this information responsibly.
